Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
201 hedge funds and large institutions have $430M invested in Revance Therapeutics, Inc. in 2024 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 40 increasing their positions, 55 reducing their positions, and 43 closing their positions.
105% more capital invested
Capital invested by funds: $209M → $430M (+$221M)
65% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 43
16% more funds holding
Funds holding: 173 → 201 (+28)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less call options, than puts
Call options by funds: $4.42M | Put options by funds: $5.33M
27% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 55
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$20.8M |
| 2 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$20.7M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$15.6M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$12.4M |
| 5 |
WIC
Water Island Capital
New York
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$35.8M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$18.1M |
| 3 |
JP Morgan Chase
New York
|
-$14M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11.1M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$9.84M |
RVNC Hedge Fund Activity: Q3 2024 in Review
201 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2024, worth a combined $430M — up 105% from $209M a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new RVNC positions and 43 closed out — a net gain of 28 holders — while 40 added to existing stakes and 55 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $20.8M. The largest seller was Capital World Investors, exiting entirely with an estimated $35.8M sold.
- 201 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2024, up from 173 in Q2 2024.
- Funds reported $430M of Revance Therapeutics, Inc. stock for Q3 2024, up 105% quarter-over-quarter.
- 71 funds opened new Revance Therapeutics, Inc. positions in Q3 2024 and 43 closed out, a net change of +28 holders.
- The largest Revance Therapeutics, Inc. buyer in Q3 2024 was Fidelity International, an estimated $20.8M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2024 was Capital World Investors, an estimated $35.8M sold.
Based on aggregated 13F filings for Q3 2024.